Canaccord lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $11 from $12 and keeps a Buy rating on the shares. The firm believes TriSalus has the foundation of a strong medical device business with a commercial footprint and catalysts to support it including new product launches and clinical data.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks